Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

• S10 ribosomal protein, cross-reactivity with anti-Sm, 1040
• Salivary glands
  • anti-Ro/SSA and anti-La/SSB in SS, 2238
  • and human T lymphotropic virus I in SS, 1972
• Salmonella, synovial endothelium binding increase in acute infection with, 1054
• Sarcoidosis
  • DEK oncoprotein autoantibodies, with SLE and, 1505
  • phalangeal osseous, 176
• Scleroderma. See Systemic sclerosis (SSc)
• Secretoneurin, in fibromyalgic muscle tissue, 1689
• Segmental mediolytic arteriopathy, mimicking polyarteritis nodosa, 935
• Selectins
  • in polyarteritis nodosa, 435
  • in rheumatoid nodules, 1783
• Serotonin, in fibromyalgic muscle tissue, 1689
• Sex, variations in RA phenotype due to, 817
• Sjogren's syndrome (SS)
  • anti-Ro/SSA and anti-La/SSB in salivary glands and, 2238
  • human T lymphotropic virus I in, 1972
  • -like disease in C57BL/6-lpr/lpr mice, 2175
  • murine model of, 150
• Skin
  • in SSc, histidinohydroxylsinonorleucine in, 376
  • in SSc, Vδ1+ in, 327
  • TNFRI effect on, 139
• Skin cancer, and cyclosporine treatment risks in RA, 1930
• Slide competition, winners of 1998 American College of Rheumatology, 2106
• Smoking
  • in giant cell (temporal) arteritis, cardiovascular risk factors and, 1960
  • RA and, 184
• Socioeconomic factors, versus genetics in SLE, 1161, 1173
• Sodium hyaluronate, pseudogout following intraarticular injection of, 939
• Soluble interleukin-2 receptor (sIL-2R), in Churg-Strauss syndrome, 445
• Splenic B1a cells, expanded, in NZM2410 lupus-prone mice, 1652
• Spondylarthritis, juvenile HLA-B27-associated, drug-induced pancytopenia in, 1899
• Spondylarthropathy
  • in HLA-B27 positive and negative blood donors, 58
  • MRI in knee synovitis in, 694
  • prevalence in United States, 778
• SSA/Ro and SSB/La antibodies, 927, 1625, 2238
• Staphylococcal infection, hand, in limited SSc, 373
• Steroids
  • actions of, in rheumatic diseases, 761
  • in JRA, 1210
  • in osteonecrosis, 1709
  • in RA, 564, 1203, 1709, 1710
  • in SSc renal crisis, 1613
  • in Th1/Th2 balance, 1897
• Streptococcal infection, HLA associations in poststreptococcal reactive arthritis, 1096
• Stromelysin 1 (MMP-3)
  • in collagen-induced arthritis and cartilage destruction, 110
  • inhibition by interleukin-4 in synovial fibroblasts, 1398
  • paclitaxel inhibition of expression of, 869
• Substance P, in fibromyalgic muscle tissue, 1689
• Sulfasalazine (SSZ), in the treatment of juvenile chronic arthritis, 808
• Symmetric polyarthritis, intravascular lymphoma presenting as, 1127
• Synovial cells
  • cartilage oligomeric matrix protein in, 997
  • interleukin-1 type 1 receptors in, 515
  • in RA, 48, 246
  • in RA and jun D, 470
• Synovial endothelium, binding increase in acute infection with Salmonella, 1054
• Synovial fibroblasts
  • interleukin-4 and matrix metalloproteinase transcription in, 1398
  • nuclear factor [gk]B/p50 activation of distal metalloproteinase-1 promoter in, 1987
• Synovial mast cells, in RA, 233
• Synovial tissue
  • bacterial DNA detection by 16S rRNA-PCR in, 535
  • in inflammatory arthritis, cyclooxygenase 1 and cyclooxygenase 2 in, 122
  • in RA, interferon-12 expression in, 306
  • in RA, measuring inflammation in, 663
  • in RA, single-cell analysis of T cell cytokines, 1669
• Synovial xenograft, induction of apoptosis in RA, 1251
• Synoviocytes
  • matrix metalloproteinase 1 and tissue inhibitor of metalloproteinases 1 in, 1748
  • in RA, gene identification in, 1356
  • in RA, monoclonal expansion, 1979
• Synovitis
  • heparan sulfate proteoglycan in rheumatoid, 1365
  • preceding clinically manifest RA, 1481
  • rheumatoid, CD4+ CD28- subsets in, 2108
  • in spondylarthropathy, MRI in knee, 694
  • treatment with anti-reshaping human interleukin-6 receptor monoclonal antibody, 2014
• Synovium
  • cytokine regulation of activated leukocyte cell adhesion molecule in monocytes and RA, 2221
  • hprt mutant T cells in RA and, 1772
• Systemic Lupus Activity Measure (SLAM), 1173
• Systemic lupus erythematosus (SLE)
  • in African-origin populations, 2091
  • antigen-specific antibody responses after immunizations in, 1828
  • antineuronal antibodies in pathogenesis of neuropsychiatric, 1819
  • anti-ribosomal P antibodies in pathogenesis of neuropsychiatric, 1819
  • apoptosis in, 205, 596, 823, 1152, 1241
  • assessment indexes for, 2276
  • 2CdA in the treatment of glomerulonephritis in, 335, 1704
  • corticosteroid-induced osteoporosis in, 171
  • DEK oncoprotein autoantibodies with sarcoidosis and, 1505
  • disease activity score (DAS versus DAS28), 940
  • drug therapy and SSc renal crisis, 1613
  • αEβ7 in, 1456
  • erythrocyte-mediated inhibition of immune complex deposition in, 613
  • factor B in C2-deficient, 427
  • Fas/Fas ligand in, 344, 596, 823, 1251
  • FcγRIIa alleles in, 421, 1181
  • FcγRIIa as risk factor in, 1813
  • genetic versus socioeconomic factors in, 1161
  • interleukin-12 production decrease in, 838
  • interleukin-10 promoter polymorphisms in, 1091
  • lupus nephritis, recurrent, after renal transplantation in, 678
  • mannose-binding lectin gene, associated with promoter polymorphisms of, 1663
  • memory T cells, in SLE-associated glomerulonephritis, 335
  • MRI in, cognition and, 41
  • naive T cells, in SLE-associated glomerulonephritis, 335
  • ovarian failure in cyclophosphamide-treated, 831
  • peripheral blood stem cell transplantation remission of, 2271
  • plasmapheresis-treated, severe infections in, 414
  • polymorphic CYP17 allele in, 940
  • predictors of early disease course in, 1173
  • prevalence in United States, 778
  • renal transplantation in, cyclosporine-era, 1438
  • risk factors in the development of, 1714
  • tumor necrosis factor α, 205
  • updating ACR criteria for, 751
• Systemic sclerosis (SSc)
  • -associated Raynaud's phenomenon, oral iloprost in, 670
  • avocado/soybean unsaponifiables in, 1705
  • in Choctaw, 1725, 1729
  • histidinohydroxylsinonorleucine in skin in, 376
  • HLA and anti-Th/To antibodies in, 74
  • HLA class II and tumor necrosis factor alleles in anti-topoisomerase I responders in, 1306
  • human cytomegalovirus and vasculopathy of, 10
  • α1(I) procollagen gene expression in, 2048
  • limited, RA overlap and, 1938
  • limited, staphylococcal infection and calcification in, 373
  • microsatellite markers associated with, 1729
  • occupational quartz/metal dust exposure and risk of, 1306
  • occupational solvent exposure and risk of, 1111
  • paraparesis in, 1321
  • prevalence in United States, 778
  • prostacyclin in, 466, 559
  • renal crisis, drug therapy in, 1613
  • -rheumatoid arthritis syndrome, 757, 758
  • T cell inhibition of collagen type I production in, 2039
  • tendon friction rubs in, predictive value of palpable, 186
  • upper intestinal manometry in, 1874
  • Vδ1+ T cells in skin in, 327